Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial
Top Cited Papers
- 24 July 2019
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 72 (1), 125-136
- https://doi.org/10.1002/art.41055
Abstract
Objective T cells play a key role in the pathogenesis of early systemic sclerosis. This study was undertaken to assess the safety and efficacy of abatacept in patients with diffuse cutaneous systemic sclerosis (dcSSc). Methods In this 12‐month, randomized, double‐blind, placebo‐controlled trial, participants were randomized 1:1 to receive either subcutaneous abatacept 125 mg or matching placebo, stratified by duration of dcSSc. Escape therapy was allowed at 6 months for worsening disease. The coprimary end points were change in the modified Rodnan skin thickness score (MRSS) compared to baseline and safety over 12 months. Differences in longitudinal outcomes were assessed according to treatment using linear mixed models, with outcomes censored after initiation of escape therapy. Skin tissue obtained from participants at baseline was classified into intrinsic gene expression subsets. Results Among 88 participants, the adjusted mean change in the MRSS at 12 months was −6.24 units for those receiving abatacept and −4.49 units for those receiving placebo, with an adjusted mean treatment difference of −1.75 units (P = 0.28). Outcomes for 2 secondary measures (Health Assessment Questionnaire disability index and a composite measure) were clinically and statistically significantly better with abatacept. The proportion of subjects in whom escape therapy was needed was higher in the placebo group relative to the abatacept group (36% versus 16%). In the inflammatory and normal‐like skin gene expression subsets, decline in the MRSS over 12 months was clinically and significantly greater in the abatacept group versus the placebo group (P < 0.001 and P = 0.03, respectively). In the abatacept group, adverse events occurred in 35 participants versus 40 participants in the placebo group, including 2 deaths and 1 death, respectively. Conclusion In this phase II trial, abatacept was well‐tolerated, but change in the MRSS was not statistically significant. Secondary outcome measures, including gene expression subsets, showed evidence in support of abatacept. These data should be confirmed in a phase III trial.Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K24 AR063120, R01 AR‐07047)
- National Institute of Allergy and Infectious Diseases (5UM1AI110557)
- Bristol-Myers Squibb
This publication has 32 references indexed in Scilit:
- A TGFβ-Responsive Gene Signature Is Associated with a Subset of Diffuse Scleroderma with Increased Disease SeverityJournal of Investigative Dermatology, 2010
- Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: Analysis of three large multicenter, double‐blind, randomized controlled trialsArthritis & Rheumatism, 2009
- Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2009
- Molecular Subsets in the Gene Expression Signatures of Scleroderma SkinPLOS ONE, 2008
- Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatmentArthritis Care & Research, 2008
- Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: Application of a latent linear trajectory modelArthritis & Rheumatism, 2007
- Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine studyAnnals Of The Rheumatic Diseases, 2006
- Early T cell activation in the skin from patients with systemic sclerosisAnnals Of The Rheumatic Diseases, 2005
- Lymphocytes in the skin of patients with progressive systemic sclerosisArthritis & Rheumatism, 1984
- Cellular infiltrates in scleroderma skinArthritis & Rheumatism, 1977